Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04780893
Other study ID # NIPTSD01
Secondary ID
Status Withdrawn
Phase N/A
First received
Last updated
Start date February 1, 2022
Est. completion date April 2022

Study information

Verified date January 2024
Source Neurovalens Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This double blind randomized controlled study will enroll 20 subjects and will be conducted remotely. The study will be randomized for an 8-week period with a 1:1 active to sham device allocation. Primary endpoint analysis will be performed at 4 weeks.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date April 2022
Est. primary completion date April 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion criteria: 1. Signed informed consent 2. Diagnosed PTSD by a medical practitioner 3. Post-Traumatic Checklist (PCL-5) score of 31 or above 4. Insomnia Severity Index (ISI) score of 15 or above 5. Male or female, age = 18 years and = 80 years at the time of signing informed consent 6. Ability and willingness to complete all study visits and procedures, including completion of mental health questionnaires 7. Ability and willingness to adhere to 30 minutes usage of the device daily for the duration of the study 8. No change to PTSD, mental health or insomnia medication within the past 3 months (regimen should be stable) 9. Agreement not to change usage of prescription or over the counter PTSD, mental health or insomnia medications for the duration of the study 10. Agreement not to undergo any significant lifestyle changes that may affect sleep (e.g., excessive exercise, sleep interventions etc.) for the duration of the study 11. Agreement not to use sleep trackers (e.g., Fitbit) for the duration of the study 12. Agreement not to travel across different time zones for the duration of the study 13. Access to Wi-Fi (to enable the study app to upload usage data) 14. Access to computer, laptop, iPad or tablet (to conduct remote study visits and complete study questionnaires remotely) 15. Willing to download and use Zoom (to conduct remote study visits) Exclusion criteria: 1. History of skin breakdown, eczema, or other dermatological condition (e.g., psoriasis) affecting the skin behind the ears 2. Previous diagnosis of HIV infection or AIDS (HIV is known to cause vestibular neuropathy which would prevent VeNS from working) 3. Use of beta-blockers within 1 month of starting the study 4. A history of stroke or severe head injury as defined by a head injury that required a craniotomy or endotracheal intubation (in case this damaged the neurological pathways involved in vestibular stimulation) 5. Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.) 6. Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using an adequate contraceptive method 7. Diagnosis of epilepsy 8. Diagnosis of active migraines 9. Previous use of Modius device 10. Participation in other research studies sponsored by Neurovalens 11. Participation in any other sleep or PTSD studies 12. Not fluent in English language 13. Have a member of the same household who is currently participating in this study 14. Failure to agree to use of device daily during study participation 15. History of vestibular dysfunction or other inner ear disease 16. Any other medical condition, or medication use, that in the opinion of the PI is likely to make the subject refractory to VeNS.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Modius Sleep
The device utilizes a technology called vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 30 minutes per day.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Neurovalens Ltd. Clinical Trial Mentors

Outcome

Type Measure Description Time frame Safety issue
Primary Insomnia Severity Index (ISI) score To evaluate the effect of the Modius Sleep device, relative to control group on participants with insomnia. ISI is a self-report rating scale assessing the severity of insomnia symptoms (range 0-28) with higher scores indicating a more severe insomnia. 4 weeks
Secondary PCL-5 Score To evaluate the effect of the Modius Sleep device, relative to control group, on the symptoms of PTSD, quantified by change in the PCL-5 Score. 4 weeks
Secondary SF-36 Score To evaluate the effect of the Modius Sleep device, relative to control group, on quality of life, quantified by change in the SF-36 Score. 4 weeks
Secondary Generalised Anxiety Disorder (GAD-7) Scores To evaluate the effect of the Modius Sleep device, relative to control group, on anxiety, quantified by change in the GAD-7 score. GAD-7 is a self-report rating scale assessing the severity of anxiety (range 0-21), with higher score indicating more severe anxiety. 4 weeks
Secondary Prescription reduction To evaluate the effect of the Modius Sleep device, relative to control group, on prescription reduction, quantified by change in medication. 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT04512768 - Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy N/A
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Completed NCT06339853 - Study of Efficacy of Digital Cognitive Behavioral Therapy With Wearable Device for Insomnia N/A
Recruiting NCT04069247 - Effectiveness of eCBT-I on Improving Mental Health in Chinese Youths With Insomnia N/A
Completed NCT04493593 - Internet-delivered CBT-I (Space for Sleep): Pilot and Feasibility N/A
Recruiting NCT06278077 - Neurexan - a Clinical Trial in Short-Term Insomnia Patients Phase 2
Recruiting NCT05956886 - Sleep Chatbot Intervention for Emerging Black/African American Adults N/A
Completed NCT04661306 - The Better Sleep for Supporters With Insomnia Study N/A
Recruiting NCT06207279 - Preliminary Study on the Development and Reliability and Validity of Attention Rating Scale
Recruiting NCT06006299 - Investigating the Use of taVNS to Treat Insomnia in Individuals With Breast Cancer (taVNS-insomnia-BC) N/A
Completed NCT03683381 - App-based Intervention for Treating Insomnia Among Patients With Epilepsy N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT04035200 - Safety, Tolerability and Efficacy Study of V117957 in Subjects With Insomnia Associated With Alcohol Cessation Phase 2
Active, not recruiting NCT05027438 - Reducing Use of Sleep Medications Assisted by a Digital Insomnia Intervention N/A
Recruiting NCT06053840 - An Open-label Trial to Evaluate the Safety and Efficacy of Chloral Hydrate in Patients With Severe Insomnia Phase 4
Not yet recruiting NCT06348082 - Project Women's Insomnia Sleep Health Equity Study (WISHES) N/A
Not yet recruiting NCT06363799 - Osteopathic Protocol for Insomnia in College Students N/A
Not yet recruiting NCT05991492 - Improving Sleep With a Digital Cognitive Behavioral Therapy for Insomnia Application N/A
Not yet recruiting NCT06025968 - Digital Cognitive-behavioral Therapy for Insomnia for Patients With Multiple Sclerosis N/A